Long COVID IRIS Study Olink Proteomics Dataset

Plasma samples collected from Stanford University's “Infection Recovery in SARS-CoV-2” (IRIS) study participants during acute SARS-CoV-2 infection, approximately 3 months post infection, and approximately 12 months post infection were analyzed using the Olink® Target 96 Inflammation panel and Olink® Target 96 Immune Response panel. 

Proteomic data were obtained from the Olink biomarker platform and presented as "NPX" (i.e. Normalized Protein eXpression) for each protein assay. The dataset features de-identified patient metadata, including participant study number (i.e. IRIS_number), sex, long COVID status (0 = recovered; 1 = Long COVID), and timepoint of the plasma sample (i.e. acute infection sample, approximately 3 months post infection, or approximately 12 months post infection). 

Notes:

• Consistent with the World Health Organization (WHO) definition, long COVID was defined in this study as the continuation or development of symptoms three months after SARS-CoV-2 infection, which were not readily attributable to other etiologies.
• For acute infection samples, long COVID status (0 = recovered; 1 = Long COVID) refers to whether the patient will have fully recovered or will have long COVID at 3 months post infection. 
• For 3 month samples, long COVID status (0 = recovered; 1 = Long COVID) refers to whether the patient has fully recovered or has long COVID at 3 months post infection.
• For 12 month samples, long COVID status (0 = recovered; 1 = Long COVID) refers to whether the patient has fully recovered or has ongoing long COVID at 12 months post infection, but these patients all had long COVID at 3 months post infection.